Journal of Cell Science & Therapy

Journal of Cell Science & Therapy
Open Access

ISSN: 2157-7013

+44 1300 500008

Thyroid hormones growth factor effect in ovarian cancer: Old players, new game


4th World Congress on Cell Science & Stem Cell Research

June 24-26, 2014 Valencia Conference Centre, Valencia, Spain

Elena Shinderman

Posters: J Cell Sci Ther

Abstract :

Introduction: Ovarian carcinoma is the fifth most common cancer in women. As this disease remains challenging and highly resistant, novel treatments are urgently needed. α v β 3 integrin is a plasma membrane receptor which is over-expressed on many cancer cells, including ovarian cancer. This receptor recognizes RGD motifs on extra cellular proteins and takes part in adhesion and signaling processes. Recently, a novel non-RGD site has been described, binding mainly thyroid hormones (T3 and T4) and activating the MAPK pathway. It was aimed to study the mitogenic effects of the thyroid- α v β 3 axis, for the first time in ovarian cancer models. Methods: Ovarian cancer cell lines (OVCAR-3, SKOV-3 and A2780) were grown with/without T3/T4 (0.1nM-1 μ M) in the presence/absence of integrin antagonists and analyzed by: cell counts (FACS, CyQuant), viability (WST-1), proliferation (BrdU), cell cycle (FACS,PI), cell death (Annexin-PI, FACS), α v β 3 expression (FACS, IF) and MAPK signaling (Westerns/IF). Results: It is shown that supra-physiological T3 (1nM) and physiological T4 (100nM) concentrations increase cell viability and proliferation in ovarian cancer cells. This increase was accompanied by a reduction in cell death. Following T3/T4 treatments, a quick and long lasting MAPK pathway activation was observed. These effects were efficiently reversed by several integrin blockers, in a dose dependent manner, indicating involvement of this integrin in the growth promoting action of thyroid hormones. Conclusions: Thyroid hormones exhibit growth-factor qualities in ovarian cancer cells which appear to be α v β 3 mediated. Therefore, the study proposes that blocking this axis is a novel treatment paradigm which is yet to be explored

Biography :

Fatemeh Ganji completed her M.Sc. in Development of Biology University of science and culture and Royan Institute in Tehran. Since 2012, she was accepted to collaborate as a research assistant in hematopoietic group in Royan Institute

Top